BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime have
shown promise as a treatment of fibromyalgia, but the drug required new formulation
technology for bedtime use. The present trial was designed to assess the safety and efficacy
of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.